ResMed (RMD)

Executive Summary

ResMed is a global leader in respiratory care, specializing in cloud-connected devices and digital health solutions for sleep apnea, COPD, and other chronic respiratory conditions. With a market capitalization of ~$29B, the company continues to benefit from secular tailwinds including an aging population, rising obesity rates, and increasing awareness of sleep-disordered breathing. ResMed's integrated ecosystem—combining hardware (CPAP, bilevel, and ventilator devices) with software (AirView, myAir) and data analytics—creates a sticky, recurring revenue model and sets it apart from competitors. Recent financial performance has been robust, driven by strong demand for its AirSense 11 platform and international expansion. The company also holds a significant competitive advantage through its established relationships with healthcare providers, payers, and DME suppliers. Looking ahead, ResMed's focus on digital health innovation and expansion into adjacent respiratory conditions positions it for sustained growth, though currency headwinds and competitive pressure from Philips' re-entry remain near-term risks.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance of next-generation CPAP or bilevel device with enhanced comfort features70% success
• Q4 2026Expansion of digital health subscription services (e.g., remote patient monitoring) into new geographies85% success
• Q3 2026Positive Medicare coverage decision for home sleep apnea testing or COPD therapy60% success